Company intelligence / Profile preview

General Regeneratives

Shanghai, Shanghai, Chinapitchbook.com ↗

Ownership: Private
Development stage: Phase 1

Overview

General Regeneratives is developing biologics using genetic, protein, and antibody engineering. Its lead asset is a recombinant human interleukin‑1 receptor antagonist in Phase 2 for arthritis/gout. Other assets include small molecules targeting KRAS G12D in solid tumors at Phase 1/2, with additional early-stage programs in multiple myeloma, anaphylaxis, and other cancers. The company has initiated several clinical trials since at least 2017. No approved products as of June 2025.

Therapeutic areas: OncologyRheumatologyImmunology
Modalities: Monoclonal antibodySmall moleculeRecombinant proteinBiological product
Industry: Biotech

Drug pipeline

2 assets

il-33 protein

Pre-clinical

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on General Regeneratives.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on General Regeneratives.

Explore the full profile